Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Completed

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis

NCT01806675↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome
Outcome unknown
Phase
Phase 1 / Phase 2
Status
Completed
Study type
Interventional
Start
4 March 2013
Expected end
April 2019
Enrollment
25 participants
Sites
1
Primary outcomes
Change From Baseline in Maximum Standard Uptake Values (SUVmax)
Sponsor
Other
Results posted
2019-09-06
Last update
3 October 2019

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiving antiangiogenesis treatment.

Detailed description public domain (ClinicalTrials.gov)

PRIMARY OBJECTIVE • Evaluate 18F-FPPRGD2 and 18F-FDG as PET/CT or PET/MRI radiotracers for imaging prediction and assessment of response to anti-angiogenesis therapy in participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC). SECONDARY OBJECTIVE • Progression-free survival (PFS) at up to 1 year after initial scans and treatment OUTLINE: Patients undergo 18F-FPPRGD2 and 18F-FDG PET/CT or PET/MRI medical imaging at baseline and at regular medical care follow-up (6 to 12 weeks). After completion of study imaging, patients are followed up at 12 months.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Change From Baseline in Maximum Standard Uptake Values (SUVmax) [At baseline and 6 weeks]. Median, ratio (Standard Deviation). 18F-FPPRGD2 PET scans: Glioblastoma Multiforme (GBM) (n=8): -0.98 (0.98); Gynecological Cancers (n=4): 0.09 (1.20); Renal Cell Cancer (RCC) (n=4): 0.10 (0.29). 18F-FDG PET scans: Gynecological Cancers (n=4): -1.90 (2.80); Renal Cell Cancer (RCC) (n=4): 7.8 (8.2).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Response Assessment by RANO Criteria [At baseline and 6 weeks].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Change in Tumor Size [9 to 12 weeks]. Median, centimeters (Standard Deviation). Gynecological Cancers (n=3): 0.9 (1.56); Renal Cell Cancer (RCC) (n=3): 1 (1.56).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Tumor Response Rate by EORTC Criteria [At baseline and 6 weeks]. Number, participants. Complete Response (CR): Gynecological Cancers (n=4): 2; Renal Cell Cancer (RCC) (n=4): 0. Partial Repsonse (PR): Gynecological Cancers (n=4): 1; Renal Cell Cancer (RCC) (n=4): 0. Stable Disease (SD): Gynecological Cancers (n=4): 0; Renal Cell Cancer (RCC) (n=4): 2. Progressive Disease: Gynecological Cancers (n=4): 1; Renal Cell Cancer (RCC) (n=4): 2.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Progression-free Survival (PFS) [1 year].

Papers 4

The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.